Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular ...
Johnson & Johnson expands TECNIS PureSee access, strengthening its eye care portfolio and medical technology growth narrative.
Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...
The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †. 93% of patients become free from glasses at all distances.#4 ‡ TECNIS Odyssey ...
Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...
JACKSONVILLE, Fla., June 17, 2025 /PRNewswire/ -- Johnson & Johnson, § a global leader in eye health, announced today that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC ...
Johnson & Johnson is expanding the US roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to ...
TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes. 5¶ Experience the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results